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Abstract
In nature, cholera toxin (CT) and the structurally related E. coli heat labile toxin type I (LTI) must breech the epithelial
barrier of the intestine to cause the massive diarrhea seen in cholera. This requires endocytosis of toxin-receptor complexes
into the apical endosome, retrograde transport into Golgi cisternae or endoplasmic reticulum (ER), and finally transport of
toxin across the cell to its site of action on the basolateral membrane. Targeting into this pathway depends on toxin binding
ganglioside GM1 and association with caveolae-like membrane domains. Thus to cause disease, both CT and LTI co-opt the
molecular machinery used by the host cell to sort, move, and organize their cellular membranes and substituent
components. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Colonization of the small intestine by Vibrio chol-
erae and toxigenic Escherichia coli results in diarrhea
due to massive salt and water secretion without epi-
thelial damage [1]. The secretory diarrhea is induced
in large part by the direct action of cholera toxin
(CT) or E. coli type I heat labile toxin (LTI) on
polarized intestinal epithelial cells and is mediated
by an increase in intracellular cAMP generated by
adenylate cyclase [2,3]. Movement of toxin into the
cell by endocytosis and vesicular transport is re-
quired for bioactivity. This depends exclusively on
interactions of toxin with the target cell as neither
V. cholerae nor toxigenic E. coli invade the epithe-
lium or assist the delivery of toxin into the cell by
other mechanisms.
The human intestine is lined with a continuous
monolayer of polarized epithelial cells that exhibit
circumferential tight intercellular junctions sealing
one cell to another and preventing passive di¡usion.
This single-cell thick monolayer forms the rate-limit-
ing barrier against solute transport and microbial
invasion, both of which are essential for intestinal
function. To gain entry into the epithelial barrier,
both CT and LTI co-opt the molecular machinery
used by the host epithelial cell to sort, move, and
organize their cellular membranes and substituent
components. This depends on the ability of CT and
LTI to opportunistically bind a speci¢c cell surface
lipid, ganglioside GM1, for entry and navigation
through the cell. For V. cholerae, this was a critical
evolutionary choice as binding to other endogenous
or experimentally created cell surface receptors,
whether protein or lipid, renders the toxin inactive
[4^6].
Over the last 30 years, studies on the biology of
cholera toxin have impacted signi¢cantly on diverse
¢elds in the life sciences including signal transduc-
tion, mucosal immunology, lipid and protein bio-
chemistry, and more recently membrane dynamics.
This review will focus on membrane dynamics. We
attempt to summarize the evidence that CT and LTI
must utilize endogenous mechanisms of vesicular
transport to enter the cell and induce disease. The
membrane systems engaged by CT and LTI are fun-
damental to the structure and function of eukaryotic
cells themselves. In transporting epithelia, membrane
tra⁄c accounts ultimately for the formation and
maintenance of cell polarity and thus the ability of
the epithelium to separate distinct compartments and
regulate the transport of water, solutes, and micro-
organisms between the outside world and the inter-
stitium.
2. Toxin structure
CT and LTI are closely related toxin’s whose A-
and B-subunits have been de¢ned structurally at
1.25^2.3 Aî resolution [7^10] (Fig. 1). The B-subunit
is comprised of ¢ve identical polypeptides (11.5 kDa)
that assemble into a highly stable pentameric ring.
The A-subunit is a single polypeptide (28 kDa) com-
prised of two major domains (A1 and A2). The two
domains are linked by a surface exposed loop which
contains a site for proteolytic cleavage and a single
disul¢de bond which bridges the cleavage site
[8,9,11].
The assembled pentameric B-subunit (55 kDa)
binds stoichiometrically to ¢ve GM1 molecules on
the host cell plasma membrane with high a⁄nity
(Kd and 6 1 nM) and speci¢city. The A-subunit ex-
hibits enzymatic activity as a combined ADP-ribosyl-
transferase and NAD glycohydrolase [12,13]. Proteo-
lytic cleavage within the exposed loop connecting the
two domains of the A-subunit and reduction gener-
ates the enzymatically more active A1-peptide (W22
kDa) [14]. The A1-peptide must enter the cytoplasm
to activate adenylyl cyclase by catalyzing the ADP-
ribosylation of the K-subunit of the heterotrimeric
GTPase Gs (reviewed in [11]). The A2-peptide (W5
kDa) interacts extensively, but non-covalently, with
the central core of the B-subunit pentameric ring
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[9,10] and forms the sca¡olding which tethers the A1-
peptide and B-subunits together. The A2-peptide also
exhibits a C-terminal ER-targeting motif K(R)DEL.
The K(R)DEL residues protrude from the pentame-
ric B-subunit on the side that binds GM1 at the cell
surface, where they may plausibly interact with mem-
brane receptors [8].
3. Toxin action: the view prior to 1990
Elegant and persuasive studies over the last 30
years have de¢ned the A-subunits of CT and LTI
as potent ADP-ribosyltransferases and NAD-glyco-
hydrolases in vivo and the small GTP-binding pro-
tein family of ADP-ribosylating factors (ARF) as
allosteric co-factors for this reaction in vitro [15^
17]. In both intact and broken cells, the A-subunits
catalyze the ADP-ribosylation of the regulatory het-
erotrimeric GTPase GsK. The reaction inactivates the
intrinsic GTPase activity of the G-protein and thus
induces a prolonged activation of adenylyl cyclase
with associated rise in intracellular cAMP and con-
comitant cellular response(s) [18^20].
The B-subunits of both toxins have been de¢ned
clearly as pentameric lectins with high a⁄nity and
speci¢city for ganglioside GM1. GM1 was identi¢ed
as the sole functional receptor for CT (reviewed re-
cently in [11,21,22]), but the B-subunit of LTI also
displays a⁄nity for other gangliosides in the GM1
series and unidenti¢ed cell surface galactoproteins
exhibiting polylactosylaminoglycan carbohydrates
[23,24]. Binding of LTI to a galactoprotein receptor
also results in a cellular response [25,26]. While the
A-subunit alone can activate adenylyl cyclase in bro-
ken or permeabilized cells, the B-subunit is essential
for toxin action on intact cells.
When studied in vitro using isolated or solubilized
membrane fractions, CT was found to act immedi-
ately on its substrates in an apparent di¡usion lim-
ited reaction. When applied to intact cells, however,
toxin-induced activation of adenylyl cyclase was not
detected until at least 10^40 min after CT bound to
the cell surface [27,28]. This characteristic delay in
CT and LTI action was termed the ‘lag phase’ and
was thought to represent the time required for the A-
subunit to cross the plasma membrane and interact
with Gs inside the cell [29]. The time between toxin
binding at the cell surface and toxin-induced activa-
tion of adenylyl cyclase in the cell interior corre-
sponded closely to the time required for reduction
of the A-subunit to the A1-peptide [28]. Reduction
of the A-subunit was thought to occur in the cytosol.
Only the A-subunit was found to penetrate biologic
membranes [30,31], and translocation of the A-sub-
unit into the cytosol was considered the rate-limiting
step in toxin action. All subsequent steps leading to
ADP-ribosylation of Gs and activation of adenylyl
cyclase in the cell interior were presumed to be dif-
fusion limited. On the other hand, CT was shown by
light and electron microscopy to enter endosomes
and the trans-Golgi compartment of host cells
Fig. 1. Crystal structures of CT, LTI, and LTIIb are shown viewed from the side so that the base of the B-pentamers would face the
plasma membrane of target cells and the A-subunits would face away from the membrane. B-pentamers are shown in white, A1-pep-
tides in light gray, and A2-peptides in dark gray. The  identi¢es the catalytic site in the A1-peptides. These ¢gures were kindly pro-
vided by Ethan Merritt and Wim Hol, University of Washington, Seattle, WA.
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[32,33], and it was suggested that endocytosis and
vesicular transport may play a physiologic role in
toxin function [34,35]. This role, however, remained
unde¢ned.
4. Toxin action: dependence on membrane dynamics
The current view that toxin action depends on en-
try into host cells by membrane tra⁄c rests on evi-
dence obtained from studies performed within the
last 10 years. Correlations between toxin action and
endocytosis were ¢rst made in cell fractionation stud-
ies on rat hepatocytes intoxicated with CT in vivo.
These experiments showed that reduction of the A-
subunit and activation of adenylyl cyclase were asso-
ciated with the appearance of the A1-peptide in intra-
cellular, but not plasma membrane fractions [36,37].
In rat hepatocytes, CT-induced activation of adenyl-
yl cyclase appeared to depend on endosome acidi¢-
cation, but these data were not con¢rmed in other
studies using di¡erent models of toxin action [38^40].
The idea that CT entered the host cell by mem-
brane tra⁄c was given further support by our studies
on polarized cells. In polarized intestinal epithelial
cells, the physiologic site of toxin binding on the
apical membrane is separated spatially from adenylyl
cyclase on the cytoplasmic surface of the basolateral
membrane by circumferential tight junctions. Thus,
simply translocating across the apical membrane of
polarized cells would not necessarily be su⁄cient for
bioactivity because in polarized cells the A-subunit
(or another signaling molecule) would still require
movement across the cell to activate its target e¡ec-
tor [41]. The action of CT on polarized epithelial
cells was modeled using the human intestinal cell
line T84. T84 cells grown on permeable supports
form con£uent monolayers of columnar epithelia
that exhibit high transepithelial resistance, polarized
apical and basolateral membranes, and a cAMP-
regulated Cl3 secretory pathway analogous to that
found in intact intestine [42]. This system is partic-
ularly relevant because the model requires that CT
enter the cell and transduce a signal from the apical
membrane as must occur in vivo.
Studies on polarized T84 cell monolayers showed
that signal transduction by CT applied apically de-
pended on entry into the cell by membrane tra⁄c. As
assessed by direct epi£uorescence microscopy, the ki-
netics and temperature dependencies of CT-induced
Cl3 secretion correlated closely with endocytosis and
movement of toxin inside the cell to a position con-
sistent in location with apical recycling and late en-
dosomes and Golgi cisternae (Fig. 2) [41,43]. The
strength of these correlations were enhanced by par-
allel assessment of toxin action by entry into the cell
through the contralateral basolateral membrane. Ba-
solaterally applied CT also elicited a Cl3 secretory
response, but with shorter lag phase and faster ki-
netics. Like apically applied CT, the time course and
temperature dependencies of basolaterally applied
CT also correlated with toxin movement inside the
cell to apical recycling endosomes and Golgi cister-
nae. However, the mechanisms of toxin entry via
apical or basolateral cell surfaces were shown to be
distinct as evidenced by the clear di¡erences in time
course and temperature dependencies [41]. The par-
allel assessment of toxin action by entry into the cell
through apical or basolateral membranes provided
robust internal controls for these and subsequent
studies.
Further evidence in support of the endocytosis hy-
pothesis resulted from the discovery and use of bre-
feldin A in studies on membrane dynamics. Brefeldin
A inhibits vesicular transport in the endosomal
[44,45], transcytotic [46], and exocytotic [47] path-
ways of most eukaryotic cells [48,49]. Four labora-
tory groups showed that CT-induced cellular re-
sponses were dependent on brefeldin A-sensitive
membrane tra⁄c [38,50^52]. In all studies, brefeldin
A inhibited reversibly CT-induced activation of ad-
enylyl cyclase. Brefeldin A had no detectable e¡ect
on the enzymatic activity of the A-subunit in vitro
providing evidence that inhibition of toxin action in
intact cells was due to the known e¡ects of brefeldin
A on ARF-1 mediated membrane transport [48,53].
In two studies, brefeldin A was found to inhibit the
movement of toxin into an intracellular compartment
requisite for reduction of the A-subunit to the enzy-
matically active A1-peptide [38,50]. The transport
block occurred early in the lag phase but after endo-
cytosis of toxin containing membranes. In T84 cells,
two sequential and distinct membrane transport steps
were identi¢ed. Both ‘events’ occurred after toxin
binding to the apical cell surface and after entry
into the early endosome. The ¢rst event was BFA-
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sensitive and essential for movement of the toxin into
a compartment where reduction and formation of
the A1-peptide occurred. The second event was tem-
perature sensitive and required for transduction of a
signal, presumably by movement of the A1-peptide
to its site of action on the basolateral membrane [41].
These studies showed that multi-compartmental ves-
icular transport was required for toxin action.
5. Dependence on retrograde tra⁄c into Golgi
cisternae and ER
Given that in all toxin-sensitive cells, inhibition of
toxin action correlated closely with BFA-induced dis-
ruption of Golgi structure and function [48,49], these
data suggested to most investigators that CT may
require entry into a functional Golgi complex for
bioactivity [38,50^52]. This idea was given further
credence by solution of the crystal structures for
LTI and CT [7^9] and by the discovery and charac-
terization of the KDEL-dependent ER retrieval sys-
tem in eukaryotic cells [54^57]. The KDEL receptor
[58] is a six- [59] or seven-transmembrane-domain
protein localized predominantly to the ER, inter-
mediate compartment, and the Golgi complex with
graded distribution from cis to trans [60,61]. The
receptor mediates retrieval of KDEL-containing
soluble ER-resident proteins by retrograde vesicular
transport from multiple sites within Golgi cisternae
including trans-Golgi [62^66]. Crystal structures of
both CT and LTI showed that the K(R)DEL motif
at the C-terminus of the A2-peptide extended below
the B-pentamer in a position where it could plausibly
interact with membrane bound KDEL receptors.
The idea that CT and LTI may actually move
backwards from plasma membrane to ER of target
cells was given further credence by studies on Pseu-
domonas exotoxin A (ETxA) and shiga toxin (ST).
Both toxins appeared to require entry into the ER of
host cells for bioactivity. This was shown for ETxA
in 3T3 ¢broblasts to depend on the ¢ve C-terminal
amino acids REDLK, which when removed ablated
toxicity. Toxin action was rescued by replacement
with the ER-targeting motif KDEL [67]. Similarly,
the bioactivity of shiga toxin (another AB5 toxin
structurally related to CT and LTI, [68]) was shown
to correlate with movement of toxin from plasma
membrane to ER in A431 epidermoid cells [69,70].
That CT and LTI followed a similar retrograde
Fig. 2. Entry of CT into polarized T84 cells by endocytosis. Epi£uorescence micrographs of frozen 5-Wm sections of T84 monolayers
exposed apically (A,B) or basolaterally (C,D) to 20 nM rhodamine-labeled CT for 2 h at 4‡C (A,C), or 1 h at 37‡C (B,D). CT is in-
ternalized and located within apical structures consistent in location with late or recycling endosomes and Golgi cisternae at 37‡C but
not at 4‡C. Reproduced from [41] by copyright permission of The Rockefeller University Press.
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pathway into Golgi and then ER was provided by
four independent lines of evidence. First, two labo-
ratory groups tested the e¡ects of inactivating or re-
moving the K(R)DEL motif on toxin function
[71,72]. In polarized intestinal T84 cells, inactivating
mutations of K(R)DEL in CT or LTI attenuated the
e⁄ciency of toxin action greater than 10-fold without
a¡ecting toxin binding to cell surface receptors, en-
docytosis, or the rate of intracellular degradation
[72]. These studies showed that CT and LTI inter-
acted directly with KDEL receptors and implied that
both toxins may require retrograde movement into
Golgi cisternae and ER for e⁄cient and maximal
biologic activity. These data were not reproduced,
however, in studies on Chinese hamster ovary
(CHO) cells [71]. The discrepancies between these
data sets were likely due to di¡erences in the sensi-
tivities of the experimental approaches and cell sys-
tems utilized.
In a second line of evidence, wild-type CT A-sub-
units were localized within the ER of monkey kidney
Vero cells by light microscopy and subcellular frac-
tionation. Movement of the A-subunit into ER was
observed only after a 30^60 min lag phase. This cor-
related temporally with toxin action and displayed a
dependence on intact microtubules similar to that
required for toxin-induced activation of adenylyl cy-
clase in this cell type [73]. In Vero cells, the A-sub-
unit was found to dissociate physically from the B-
subunit before entry into the ER [73,74]. In contrast,
the B-subunit moved from plasma membrane into
Golgi cisternae, but not further even after 90-min
incubations. These data implied that the entire A-
subunit (A1- and A2-peptides together) may pull
out of the central core in the B-subunit to tra⁄c
independently into the ER. While plausible in con-
cept and possibly correct, the idea that A- and B-
subunits separate physically before entry into the ER
does not ¢t all available evidence and remains to be
con¢rmed in other cell systems (discussed in greater
detail in Sections 7 and 8).
In a third line of evidence, reduction of the A-
subunit was examined in human intestinal Caco-2
cells and shown to depend on catalysis by protein-
disul¢de isomerase [75]. The interaction between CT
and protein-disul¢de isomerase occurred within the
lumen of an intracellular compartment identi¢ed as
ER by subcellular fractionation. Finally, in a fourth
line of evidence, ultrastructural studies localized CT
B-subunits within the ER of A431 cells treated with
the endoplasmic reticulum Ca2 pump (SERCA
pump) inhibitor thapsigargin [76] and of murine hep-
atocyte BNL CL.2 cells [77]. In addition, movement
of B-subunit from plasma membrane to ER in thap-
sigargin-treated cells was inhibited by pretreatment
with brefeldin A and this correlated with loss of tox-
in function [76].
All four independent experimental approaches de-
scribed above are internally and conjointly consistent
with the idea that CT A-subunit must move retro-
grade into the ER for bioactivity. Such a conver-
gence of evidence supporting the requirement for ret-
rograde transport is also true for shiga- and shiga-
like toxins [69,70,78] (which are structurally similar
to CT and LTI), Pseudomonas exotoxin A [67], and
ricin [79,80]. If tra⁄cking by shiga toxin into HeLa
cells can be a guide [81], we anticipate that CT and
LTI will be found to move directly from recycling
endosomes to trans-Golgi, bypassing late endosomes
en route from plasma membrane to ER. Recent stud-
ies show that in Vero cells retrograde transport of
CT A-subunits from Golgi cisternae to ER, like ret-
rograde transport of endogenous cellular proteins
[82], depends on sorting into COPI-coated vesicles
[83]. Speci¢cally, movement of CT A-subunits into
ER of Vero cells (assessed by epi£uorescence micros-
copy) was blocked by microinjection of inhibitory
Fab fragments against L-COP, an essential compo-
nent of COPI coats. Furthermore, sorting into this
pathway likely depends on the p24 family proteins
that are sites for COPI coatomer binding [84] as in-
hibitory Fab fragments against a member of this
family (p23) blocked movement of CT A-subunit
into the ER. Thus, like membrane proteins that ex-
hibit dilysine motifs in their cytoplasmic tails [82,85],
and soluble ER-resident proteins that exhibit C-ter-
minal KDEL signals [86^88], CT appears to move
retrograde from Golgi to ER in COPI-coated
vesicles.
6. The site and mechanism of toxin translocation
across cellular membranes
While the bulk of evidence supports the view that
CT and LTI must move retrograde into Golgi cister-
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nae and ER to elicit an e⁄cient and maximal phys-
iologic response, we still do not know exactly where
or how the A-subunit translocates across biologic
membranes. Unlike anthrax or diphtheria toxins,
which mediate translocation of their own toxic com-
ponents across cellular membranes [89^91], there is
little evidence that the B-subunits of CT or LTI can
function as conductive pores for their respective A-
subunits [92]. As detailed above, the available data
indicate instead that CT and LTI rely on membrane
systems endogenous to the host cell to enter a sub-
cellular compartment with structure and function fa-
vorable for A-subunit reduction and membrane
translocation. Based on available evidence, two plau-
sible mechanisms have been envisioned. Each hy-
pothesis emerges from the current view that CT
and LTI require retrograde transport into ER or
cis-Golgi for bioactivity and implicate unique struc-
tural and functional components of these compart-
ments to explain peptide translocation. Neither idea,
however, has been tested experimentally.
The ¢rst hypothesis arises from recent evidence
that the biosynthetic pathways of eukaryotic cells
(including yeast) are endowed with the ability to
identify and eliminate misfolded membrane and solu-
ble proteins by proteosome-dependent degradation in
the cytosol [93]. Some misfolded proteins including
MHC class I [94], the cystic ¢brosis transmembrane
regulator (CFTR) [95], yeast vacuolar protease car-
boxypeptidase Y, yeast pheromone K-factor [96], and
others (see [97] for review) have been shown to exit
the ER via reverse translocation through the Sec 61p
complex. The sec61p complex is the central compo-
nent of the protein translocation channel in the ER.
Based on these data, Hazes and Read [98] proposed
that CT and LTI (and other toxins which require
entry into ER for bioactivity such as ST and ST-
like toxins, pertussis toxin, EtxA, and ricin) may op-
portunistically utilize Sec 61p for translocation into
the cytosol. They further proposed that once in the
ER lumen, the A1-peptide masquerades as a mis-
folded protein to interact with the required molecular
machinery for reverse transport through the trans-
locon. Once exposed to the cytosol, escape from deg-
radation by the proteosome is achieved by the ab-
sence or near absence of lysines in the toxic peptide.
Lysine residues are targets for covalent addition of
ubiquitin, a peptide tag required typically for proteo-
some-dependent degradation. The exceptionally low
content of lysines in each of the toxins mentioned
above suggest that they may have evolved in part
to escape degradation by the proteosome.
The second hypothesis arises from evidence that
the A1-peptides of CT and LTI exhibit hydrophobic
behavior in aqueous solution and when membrane
bound [99,100]. These data provide reason to believe
the A1-peptide may release from the A2-peptide and
B-subunit and partition spontaneously into the hy-
drophobic core of biologic membranes [101]. Only
some membranes, however, may be able to accept
the A1-peptide. Thus, cis-Golgi or ER membranes
may exhibit unique lipid [102] and protein structure
permissive for membrane integration of the A1-pep-
tide, while plasma and endosome membranes may
not.
7. Mechanism(s) of signal transduction after
translocation
The actual cellular events following reduction and
translocation of the A-subunit in both polarized and
non-polarized cells are not known. It has largely
been assumed that after translocation the A1-peptide
can break free of cell membranes to di¡use in the
cytoplasm. This idea seems most attractive given
the A/B-subunit structure of the toxin, the clear en-
zymatic activity of the A1-peptide in cell free systems
in vitro, and the simplicity of the proposed mecha-
nism.
On the other hand, several lines of evidence indi-
cate that in intact cells, the A1-peptide may remain
membrane associated and yet enzymatically active
following translocation. First, the A1-peptide is hy-
drophobic and when reconstituted into lipid vesicles
behaves as an integral membrane protein [99,100].
Further evidence in support of this view is supplied
by studies on human ¢broblasts [103]. When CT was
applied to cell homogenates, the toxin ADP-ribo-
sylated multiple membrane and cytosolic proteins.
In contrast, when CT was applied to intact cells,
CT ribosylated only a speci¢c subset of potential
substrates. This suggests that the enzymatic A1-pep-
tide does not have access to all cytoplasmic proteins
as one would predict for a freely di¡usible cytoplas-
mic enzyme [103].
BBAMCR 14498 28-6-99
W.I. Lencer et al. / Biochimica et Biophysica Acta 1450 (1999) 177^190 183
Studies on protease-resistant toxin variants of CT
and LTI also support the idea that the A1-peptide
may not break free of the membrane after transloca-
tion. For these studies, toxin variants were prepared
with an inactivating mutation in the serine^protease
site of the C-loop which tethers the A1- and A2-pep-
tides together. Thus, the A1- and A2-peptides were
predicted to remain covalently associated after reduc-
tion in the ER. Nonetheless, when studied in human
T84 [104], Caco-2, and CHO cells [105] these pro-
tease-resistant toxins displayed clear though dimin-
ished activity. While we cannot dismiss the possibil-
ity that in all three cell lines the protease resistant
toxins were in fact cleaved at alternative sites in very
small amounts, these data indicate that physical dis-
sociation of A1- and A2-peptides may not be re-
quired for bioactivity and raise the possibility that
the A1- and A2-peptides of native toxins may never
fully dissociate after entry into the cell. Since the A2-
peptides of both CT and LT exhibit abundant non-
covalent interactions with the B-pentamer [9,14], we
have considered the possibility that domain A1 may
translocate into the membrane and exhibit enzymatic
activity in the cytosol while still tethered via the A2-
domain to the B-subunit on the contralateral mem-
brane surface. We acknowledge, however, that pro-
teolytic cleavage of the A-subunit may not be re-
quired for complete dissociation of A-subunit from
the B-pentamer. In support of this possibility, the
entire CT A-subunit including the A2-peptide ap-
peared to separate from the pentameric B-subunit
after toxin entry into Vero cells [73,74]. It has also
been proposed that CT-activated GsK, instead of the
A1-peptide, may separate from cell membranes to
activate adenylyl cyclase at remote sites in the cell
[106], but this view is not supported by available
experimental evidence on the mechanism(s) of G-
protein signal transduction [107,108].
8. An alternative hypothesis : signal transduction by
anterograde vesicular transport
We have proposed that after translocation in the
ER, the A1-peptide may remain membrane associ-
ated and regain access to adenylyl cyclase on the
plasma membrane by simply moving back out the
Fig. 3. Proposed model of toxin action on polarized epithelia.
Left panel : in polarized cells, CT must bind to GM1 on the ap-
ical membrane and activate adenylyl cyclase on the cytosolic
surface of the basolateral membrane. In vivo, the toxin is re-
stricted from access to basolateral membranes by circumferen-
tial tight junctions and the integrity of the target cell. Toxin-in-
duced activation of adenylyl cyclase leads to elevations in
intracellular cAMP which in epithelial cells of the intestinal
crypt elicits electrogenic Cl3 secretion ^ the primary transport
event responsible for the massive secretory diarrhea seen in
cholera. Right panel : proposed model of toxin action on polar-
ized epithelia. Toxin enters polarized cells by binding GM1
within caveolae-like membrane domains at the apical cell sur-
face. The CT^GM1 complex moves via apical endosomes (AE,
shaded) into trans-Golgi (TGN). In trans-Golgi, the C-terminal
K(R)DEL sorting signal on the A-subunit facilitates retrograde
movement of the CT^GM1 complex through Golgi cisternae to
ER. Reduction and translocation of the A-subunit occurs in the
ER. The A1-peptide may separate from the ER membrane after
translocation and di¡use through the cytosol to its site of ac-
tion on the basolateral membrane. Alternatively, the A1-peptide
may remain membrane associated (or reassociate with the mem-
brane) after translocation and move to the basolateral mem-
brane by entering anterograde transport vesicles and moving
back out the secretory pathway. Fusion of basolaterally tar-
geted vesicles carrying the CT^GM1 complex delivers the trans-
located A-subunit to a site near the Gs/adenylyl cyclase com-
plex on the cytosolic surface and the B-subunit to the
exocytoplasmic surface of the basolateral membrane (termed
‘indirect transcytosis’). AE, apical endosome; TGN, trans-Golgi
network and Golgi cisternae; ER, endoplasmic reticulum; BE,
basolateral endosome; AC, adenylate cyclase; Gsa, heterotri-
meric GTPase Gs.
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biosynthetic pathway in anterograde-directed trans-
port vesicles [72,109] (Fig. 3). Evidence for this idea
comes from studies on polarized T84 cells.
In nature, CT binds initially to GM1 on the apical
membrane of polarized intestinal epithelial cells, but
acts on adenylyl cyclase at the cytoplasmic surface of
the basolateral membrane [110,111]. One way for
proteins to move from apical to basolateral surfaces
of polarized epithelia is to move across the cell by
vesicular tra⁄c in a process termed transcytosis.
When tested experimentally, we found that CT en-
tered a basolaterally directed transcytotic pathway in
T84 cells [109] and that transcellular transport corre-
lated closely with toxin function [39,72,109]. Unlike
the pathway for transcytosis of pIgA [112,113], how-
ever, movement of CT across the cell was not direct
as both CT and LT required transit through Golgi
cisternae and possibly ER en route to the basolateral
membrane [72]. We have termed this process ‘indirect
transcytosis’.
Several lines of evidence support this hypothesis.
First, inactivating mutations in the ER targeting sig-
nal K(R)DEL on CT diminished the e⁄ciency and
magnitude of both transcytosis and toxin-induced
signal transduction [72]. The two were closely corre-
lated, suggesting that interaction with KDEL recep-
tors (and by implication retrograde transport into
Golgi and ER) was required for transcytosis of toxin
subunits. Second, since only the B-subunit was read-
ily detected on the exocytoplasmic surface of the ba-
solateral membrane after transcytosis, these data
provided evidence that the CT A-subunit had trans-
located to the cytoplasm (or to the cytosolic mem-
brane surface) during transport across the cell [109].
Transcytosis of CT B-subunits was correlated with a
functional response. In cells pretreated with brefeldin
A, however, CT was delivered to the basolateral
membrane in a non-functional con¢guration with
the A-subunit remaining tethered to the B-subunit
on the outside rather than inside the cell. Thus, bre-
feldin A appeared to alter the route and mechanism
of transcytosis so that entry of CT into the Golgi
cisternae or ER was inhibited, and the A1-peptide
was unable to translocate into the cell. This was cor-
related with a complete block in toxin action. These
data identi¢ed Golgi cisternae and ER as intermedi-
ary compartments through which CT must tra⁄c en
route to the basolateral membrane and strengthened
the view that indirect transcytosis and toxin action
may be mechanistically related.
Further evidence that indirect transcytosis may ac-
count for CT action was provided by kinetic studies.
These data showed that indirect transcytosis of CT
B-subunits displayed identical physical characteristics
(lag time, time course, and temperature-dependency)
with that of CT-induced signal transduction [109]. In
aggregate, these data suggested to us that both A-
and B-subunits of CT may move together from ap-
ical receptor to basolateral e¡ector by vesicular traf-
¢c. Though on opposite sides of the membrane after
A1-peptide translocation, the subunits may not fully
dissociate during transport through the cell.
Recent studies by Rodighiero et al. provide addi-
tional evidence in support of the importance of B-
subunit in toxin function [114]. These studies were
initiated to de¢ne the structural basis for the well
known di¡erences in potency of LTI and CT in vitro
and in vivo [11]. To do so, chimeric toxins were
prepared associating the A-subunits of CT with the
B-subunits of LTI and vice versa. The chimeric tox-
ins were analyzed for bioactivity in the T84 cell sys-
tem. These studies showed that the increased potency
of CT relative to LTI did not stem from di¡erences
in enzymatic activity of the A-subunits or di¡erences
in receptor recognition by the B-subunits. Rather,
the di¡erences in potencies could be attributed to
the increased ability of the A2-fragment of CT to
maintain holotoxin stability during uptake and trans-
port through the cell [114]. These studies emphasize
the importance of the B-subunit in toxin biology and
raise questions of when and where in the cell the A1-
peptide and B-subunit separate fully, if ever. In sup-
port of this view, available data indicate the structur-
ally related shiga- and shiga-like toxins also depend
on B-subunit function for entry into the ER of target
cells [69,70,78,79]. Unlike CT and LTI, shiga- and
shiga-like toxins do not exhibit K(R)DEL motifs,
and the importance of B-subunit dependent glyco-
lipid-based targeting in this system is more readily
self-evident.
In summary, the exact events which lead to CT-
induced signal transduction after A1-peptide translo-
cation in both polarized and non-polarized cells re-
main incompletely de¢ned. At this time, we interpret
the available data as evidence in favor of the idea
that the A1-peptide may remain membrane associ-
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ated and enzymatically active after translocation. In-
deed, the fact that the A1-peptide interacts with
ARF-family proteins in vitro [17] suggests to us
that the A1-peptide may be involved in directing its
own vesicular transport after membrane transloca-
tion in vivo. Abundant evidence indicates that
ARF-family GTP-binding proteins function in mem-
brane transport to induce assembly of coat proteins
for vesicular tra⁄c between ER and Golgi, within
Golgi cisternae, at exit from trans-Golgi, and be-
tween endosomes or synaptic vesicles [17,115^120].
Thus, we speculate that the A1-peptide may ensure
its own movement back out the secretory pathway by
entry into anterograde transport pathways and inter-
action with ARF. A related hypothesis would be that
ADP-ribosylated-Gs rather than the A1-peptide
moves from ER or Golgi cisternae in anterograde
directed vesicles to activate adenylyl cyclase on the
plasma membrane. Such a mechanism of signal
transduction would also depend on ARF-mediated
membrane tra⁄c and, if Gs traveled together with
CT B-subunit, would ¢t the experimental evidence
[72,109]. On the other hand, we acknowledge the
available data which support the alternative possibil-
ity that the A1-peptide may separate from the mem-
brane after translocation to di¡use freely in the cy-
tosol. This view, until proven otherwise, will always
remain attractive for its simplicity in mechanism of
action.
9. Molecular mechanisms of targeting and transport
Some of the most exciting recent work in toxin
biology has addressed the molecular mechanisms
which account for targeting CT and LTI into the
cell. Two recent studies show that this is not a sto-
chastic process. Rather, CT must associate with spe-
ci¢c lipid-de¢ned plasma membrane domains to elicit
an e¡ect [6,121].
Two laboratory groups have proposed that target-
ing CT and LTI into non-polarized [5] and polarized
cells [109] may plausibly depend on structural fea-
tures of the toxin’s endogenous receptor, ganglioside
GM1. Such a dependence on glycolipid structure and
function is also true for shiga toxin and shiga-like
toxins (which bind Gb3, [122]), E. coli heat labile
type II toxins (which bind GD1a or GD1b, [23]),
and likely tetanus toxin (which binds GD1b,
[123,124]). Glycosphingolipids, such as ganglioside
GM1, are located exclusively in the outer (exo-cyto-
plasmic) lea£et of cell membranes (reviewed in [125^
128]). They contribute to the structure and function
of membrane domains in the plasma membrane and
throughout the central vacuolar network of eukary-
otic cells, except perhaps ER where they may be
present in extremely low concentrations. Transport
between distinct intracellular membrane compart-
ments occurs only by vesicular tra⁄c. Thus, ganglio-
side GM1, which has been shown to recycle between
the cell surface and trans-Golgi network in murine
NCTC 2071 and rat glioma C6 cells [129], represents
an ideal target for toxins entering the endocytic and
retrograde secretory pathway.
The idea that ganglioside structure may a¡ect CT
and LTI function was ¢rst tested experimentally by
Pacuszka et al. [4,5] (see [21,22] for recent reviews).
To show speci¢city of structure and function, these
investigators replaced the ceramide moiety on GM1
with aliphatic amines, cholesterol, or phospholipids
and assessed these neo-ganglioside’ receptors for po-
tency in mediating CT-induced activation of adenylyl
cyclase in rat glioma C6 cells. GM1 neo-gangliosides
constructed by attaching the GM1 oligosaccharide to
cholesterol or aliphatic amines of greater than 14
carbon chain length were more potent than GM1
in mediating CT action. GM1 oligosaccharide at-
tached to phospholipids or to the protein transferrin
were less potent. Thus, receptor structure a¡ects
function.
How ganglioside structure may a¡ect toxin traf-
¢cking has been explained by two recent studies. In
many cell types, a large fraction of GM1 clusters in
caveolae [130^132]. Caveolae and related membrane
structures display light density and resistance to de-
tergent extraction by virtue of their lipid and possi-
bly protein composition [133^136]. These specialized
membrane domains exist on both intracellular [137]
and plasma membranes [138]. Caveolae are thought
to mediate key cellular functions, which include lig-
and induced signal transduction, protein and lipid
sorting, endocytosis, and (in vascular endothelium)
transcytosis [125,126,131,139^146]. Two laboratory
groups, including our own, have now shown that
caveolae-like membrane domains mediate toxin-in-
duced signal transduction in human intestinal
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Caco-2 and T84 cell lines [6,121]. Orlandi and Fish-
man used the cholesterol-binding agent ¢lipin to dis-
rupt the structure of caveolae in Caco-2 cells and this
correlated with inhibition of CT-induced activation
of adenylyl cyclase and endocytosis [121]. Wolf et al.
utilized the related E. coli heat-labile type II enter-
otoxin LTIIb to show that ganglioside structure was
critical for toxin action, and this e¡ect depended on
association of toxin with caveolae-like membrane do-
mains [6].
The two toxins used in our studies, CT and LTIIb,
distinguish between gangliosides GM1 and GD1a at
the cell surface by virtue of their dissimilar receptor
binding B-subunits [10,147]. The enzymatically active
A-subunits, however, are homologous [148,149] (Fig.
1). While both CT and LTIIb bound speci¢cally to
human intestinal T84 cells, only CT elicited a cAMP-
dependent Cl3 secretory response. LTIIb, however,
was shown to be functional and more potent than
CT in eliciting a cAMP-dependent response from
mouse Y1 adrenal cells. In T84 cells, CT fractionated
with caveolae-like detergent insoluble membranes,
but LTIIb did not. In Y1 cells, both toxins associ-
ated with caveolae-like membrane domains. Thus,
toxin function correlated with binding to ganglio-
sides within caveolae-like plasma membrane domains
suggesting the two may be related. To con¢rm these
results, chimeric toxins associating the CT A- with
LTIIb B-subunits (and vice versa) were prepared.
Analysis of these chimeric toxins showed that tox-
in-induced signal transduction and association with
caveolae depended critically on binding to ganglio-
sides with speci¢c structure, a function of the toxin’s
B-subunit. Thus, the mechanism(s) by which ganglio-
side GM1 functions in signal transduction likely de-
pends on coupling CT with caveolae or caveolae-re-
lated membrane domains. These data ¢t nicely with
earlier morphologic studies showing that CT enters
hepatocytes, ¢broblasts, A431, and endothelial cells
via smooth, non-clathrin-coated membrane invagina-
tions characteristic of caveolae [77,131,150^152].
Exactly how speci¢c gangliosides may function as
discrete sorting motifs for partitioning CT and LTI
into caveolae-like membrane subdomains, however,
remains unde¢ned. The structures of GM1 and
GD1a di¡er most signi¢cantly in their respective car-
bohydrate head groups, and even these are closely
related [153]. Nonetheless, detergent insoluble mem-
brane microdomains of human intestinal T84 cells
clearly distinguish between these similar glycolipids.
Thus, one possibility is that carbohydrate head
groups may de¢ne speci¢city in this system. If so,
these studies imply that epitopes on proteins or lipids
resident in the exoplasmic bilayer lea£et provide mo-
tifs for sorting of membrane components at the cell
surface and possibly within endosomes and other
transport vesicles (as previously proposed
[136,154]). Alternatively, glycosphingolipids exhibit
heterogeneity in structure of their lipid tails [153],
and this may also impart speci¢city to glycolipid
function as suggested by Sandvig, Mayor, and Pa-
cuszka and colleagues [5,70,155].
10. Summary and signi¢cance
In nature, CT and LTI must enter polarized epi-
thelial cells through the apical membrane. This re-
quires endocytosis of toxin^receptor complexes into
the apical endosome, retrograde transport into Golgi
cisternae and ER [38,41,50,72,73,75], and ¢nally
transport of the translocated toxin (or possibly an-
other signaling molecule) across the cell to its site of
action on the basolateral membrane. In the human
intestine, this process leads to intestinal salt and
water secretion and the massive diarrhea seen in
cholera. Targeting into this pathway depends crit-
ically on the biology and structure of the toxin’s
cell surface receptor, ganglioside GM1. Binding or
clustering GM1 sorts CT and LTI into caveolae or
caveolae-like membrane domains [4^6,121]. Thus, the
cellular basis of CT and LT action depends on mo-
lecular mechanisms which move speci¢c membranes
and membrane components throughout the cell.
Membrane dynamics are fundamental to the struc-
ture and function of eukaryotic cells themselves, and
in particular to the polarized epithelial cells which
line the gastrointestinal, renal and pulmonary sys-
tems of animals in nearly all kingdoms and phyla.
Epithelial cells lining the lumen of these organs de-
pend on vesicular transport to establish and maintain
cell polarity and function. It should be no surprise
that CT and LTI, which must interact with polarized
epithelial cells in nature, have evolved to co-opt en-
dogenous mechanisms of membrane transport for
their own advantage.
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The importance of toxin biology is underscored by
the fact that toxigenic secretory diarrheas account
for nearly 20% of the identi¢able diarrheal disease
worldwide [156,157]. In children, less than 5 years
old, diarrhea remains the leading cause of death (5
million deaths/year) [157] and a signi¢cant factor in
malnutrition [158]. Several other deadly enterotoxins,
such as shiga- and shiga-like toxins, are related struc-
turally to CT and LTI and also require entry into the
cell by glycolipid-dependent vesicular transport. Fur-
ther de¢nition of the cellular mechanisms which ac-
count for the bioactivities of CT and related toxins
may lead ultimately to new approaches of high im-
pact for the prevention and treatment of these com-
mon diarrheal diseases.
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